EntryPoint Capital LLC Grows Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

EntryPoint Capital LLC grew its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 328.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 53,443 shares of the company's stock after purchasing an additional 40,964 shares during the quarter. EntryPoint Capital LLC's holdings in Roivant Sciences were worth $632,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. GAMMA Investing LLC grew its stake in Roivant Sciences by 57.0% in the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock worth $42,000 after purchasing an additional 1,288 shares in the last quarter. PNC Financial Services Group Inc. grew its position in shares of Roivant Sciences by 27.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock worth $84,000 after buying an additional 1,507 shares in the last quarter. Quarry LP increased its stake in shares of Roivant Sciences by 50.0% during the third quarter. Quarry LP now owns 7,500 shares of the company's stock valued at $87,000 after buying an additional 2,500 shares during the period. Blue Trust Inc. raised its holdings in shares of Roivant Sciences by 550.1% in the fourth quarter. Blue Trust Inc. now owns 7,879 shares of the company's stock valued at $91,000 after acquiring an additional 6,667 shares in the last quarter. Finally, HighTower Advisors LLC bought a new stake in shares of Roivant Sciences in the fourth quarter valued at about $121,000. 64.76% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ROIV. HC Wainwright reiterated a "buy" rating and set a $18.00 target price on shares of Roivant Sciences in a report on Tuesday, February 11th. Cantor Fitzgerald upgraded shares of Roivant Sciences to a "strong-buy" rating in a research note on Tuesday, March 4th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $17.10.

Remove Ads

Insider Activity

In related news, CAO Rakhi Kumar sold 227,500 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $10.43, for a total value of $2,372,825.00. Following the transaction, the chief accounting officer now owns 163,264 shares in the company, valued at approximately $1,702,843.52. This represents a 58.22 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Sciences Ltd. Roivant acquired 16,845,010 shares of the firm's stock in a transaction on Monday, January 13th. The shares were acquired at an average price of $20.00 per share, with a total value of $336,900,200.00. Following the completion of the purchase, the director now owns 96,650,341 shares in the company, valued at approximately $1,933,006,820. This trade represents a 21.11 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 1,573,245 shares of company stock valued at $17,079,242. Company insiders own 7.90% of the company's stock.

Roivant Sciences Trading Down 1.0 %

Shares of NASDAQ:ROIV traded down $0.10 during trading on Friday, reaching $10.38. The stock had a trading volume of 3,942,656 shares, compared to its average volume of 5,393,763. The firm's 50-day simple moving average is $10.74 and its 200 day simple moving average is $11.41. Roivant Sciences Ltd. has a one year low of $9.96 and a one year high of $13.06. The company has a market capitalization of $7.41 billion, a P/E ratio of -69.20 and a beta of 1.26.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Equities research analysts forecast that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.